{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:45:25Z","timestamp":1786193125874,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR1015B"],"award-info":[{"award-number":["SHDC2020CR1015B"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ard.2025.10.010","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:17:57Z","timestamp":1762431477000},"page":"489-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2570-4576","authenticated-orcid":false,"given":"Fangfang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Ming","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-5768","authenticated-orcid":false,"given":"Shuang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ard.2025.10.010_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","article-title":"Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus","volume":"78","author":"Oon","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2025.10.010_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103773","article-title":"Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force","volume":"24","author":"Piga","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.ard.2025.10.010_bib0003","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1016\/S2665-9913(20)30004-7","article-title":"Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Sun","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.10.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000339","article-title":"Varicella zoster virus infections increase the risk of disease flares in patients with SLE: a matched cohort study","volume":"6","author":"Sun","year":"2019","journal-title":"Lupus Sci Med"},{"issue":"12","key":"10.1016\/j.ard.2025.10.010_bib0005","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"10.1016\/j.ard.2025.10.010_bib0006","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ard.2025.10.010_bib0007","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.10.010_bib0008","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/mr\/road078","article-title":"Real-world efficacy of belimumab in achieving remission or low-disease activity in systemic lupus erythematosus: a retrospective study","volume":"34","author":"Hasegawa","year":"2024","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.10.010_bib0009","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/biomedicines11030962","article-title":"Effectiveness and safety of belimumab in chinese lupus patients: a multicenter, real-world observational study","volume":"11","author":"Sun","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ard.2025.10.010_bib0010","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.ard.2025.06.1849","article-title":"ABS0460 The BLyS lupus flare index (BLyFI): a decision-making tool for immunosuppressive therapy withdrawal in remitted SLE patients","volume":"84","author":"Merra","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.10.010_bib0011","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/0961203315604909","article-title":"Elevated BLyS levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab","volume":"25","author":"Roth","year":"2016","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.ard.2025.10.010_bib0012","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2025.10.010_bib0013","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ard.2025.10.010_bib0014","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/oxfordjournals.qjmed.a068841","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"Q J Med"},{"issue":"24","key":"10.1016\/j.ard.2025.10.010_bib0015","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ard.2025.10.010_bib0016","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1002\/art.39296","article-title":"Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin","volume":"67","author":"Wang","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.10.010_bib0017","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10155","key":"10.1016\/j.ard.2025.10.010_bib0018","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"issue":"10143","key":"10.1016\/j.ard.2025.10.010_bib0019","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ard.2025.10.010_bib0020","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.10.010_bib0021","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.10.010_bib0022","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ard.2025.10.010_bib0023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.10.010_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000634","article-title":"Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria","volume":"9","author":"van Vollenhoven","year":"2022","journal-title":"Lupus Sci Med"},{"issue":"3","key":"10.1016\/j.ard.2025.10.010_bib0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the systemic lupus international collaborating Clinics\/American College of Rheumatology Damage Index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725044498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725044498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:26:44Z","timestamp":1786192004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725044498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0003496725044498"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.10.010","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}